Diabetes Core Update

Is hypercortisolism the hidden culprit in a significant proportion of both difficult-to-treat diabetes and resistant hypertension? In part 4 of our special series, Dr. Neil Skolnik speaks with John Buse, MD to explore the effects of hypercortisolism, until just recently considered a vanishingly rare condition.
This special episode is sponsored with support from Corcept.
Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
John Buse, MD, The Verne S. Caviness Distinguished Professor and director of the Diabetes Center at the University of North Carolina at Chapel Hill School of Medicine, a past president of medicine & science at the American Diabetes Association (ADA), and recipient of the ADA Outstanding Achievement in Clinical Diabetes Research Award
Selected references:
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care April 2025
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment. Diabetes Care June 2025
MOMENTUM: Hypercortisolism Present in 1-in-4 with Resistant Hypertension. HCP Live March 2026

We have only recently become aware of the close relationship between the heart and the kidneys. In today's discussion, Dr. Neil Skolnik speaks with Dr. Josephine Harrington to gain insight into these newly-discovered links between cardiovascular risk and CKD.
This special episode is sponsored with support from Bayer.
Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Josephine Harrington, M.D., Assistant Professor of Medicine in the Division of Cardiology at the University of Colorado School of Medicine.
Selected references:
Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229
Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121

In the early 2000s, long-acting, once-daily insulin was approved, completely changing the experience of using insulin for people with diabetes. But science doesn't stand still. Now the FDA has approved weekly insulin. In this special episode of Diabetes Core Update, Neil Skolnik speaks with Athena Philis-Tsimikas, MD about this exciting development.
This special edition of Diabetes Core Update is sponsored with support from Lilly.
Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Athena Philis-Tsimikas, MD, Corporate Vice President of the Scripps Whittier Diabetes Institute and Diabetes Care Line at Scripps Health in San Diego, CA

Welcome to the latest episode (May 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease.
This month, they discuss:
Marston NA, Bohula EA, Bhatia AK, et al. "Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial." JAMA. 2026;335(16):1400–1407. doi:10.1001/jama.2026.3277

Lee YJ, Lee SJ, Kim JW, et al. "Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease." N Engl J Med 2026;394:1365-1375. doi:10.1056/NEJMoa2600283

Nissen SE, Wolski K, D'Alessio D, et al. "Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial." JAMA Cardiol. Published online March 28, 2026. doi:10.1001/jamacardio.2026.0767

Moura FA, et al. "Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis." Diabetes Care. 2026;49(5):724–729. doi.org/10.2337/dc25-1238

Ostrominski JW, Ortega-Montiel J, et al. "Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations." Diabetes Care. 2026;49(5):808–817 doi.org/10.2337/dc25-3063

Nicole Napoli, "Shingles Vaccine Drastically Cuts Risk of Serious Cardiac Events." The American College of Cardiology. March 17, 2026 https://www.acc.org/About-ACC/Press-Releases/2026/03/16/19/33/Shingles-Vaccine-Drastically-Cuts-Risk-of-Serious-Cardiac-Events

For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.

In this special edition on Emerging Technologies for People with Diabetes our host, Dr. Neil Skolnik will discuss recent and future advances in technologies for people with diabetes. This special episode is supported by an independent educational grant from Seagrove Partners.
Presented by:
Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Erik Veerhoef, Founder, President and CEO of Seagrove Partners